Clinical Trial Update: Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults [Phase 3]

View source ↗

Summary

Phase 3 trial update for PF-07055480 Giroctocogene fitelparvovec gene therapy in adults with moderately severe to severe Hemophilia A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• PF-07055480 / Giroctocogene Fitelparvovec (giroctocogene fitelparvovec)

Snippet

Sponsor: Pfizer | Conditions: Hemophilia A | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-08-17